Medpal AI Regulatory News (MPAL)

10 November 2025

MedPal AI plc

("MedPal AI" or the "Company")

NHS Contract Approval

Operational Update

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to announce that its wholly owned subsidiary, MedPal Limited, has received formal approval from Norfolk and Waveney Integrated Care Board ("ICB") for the change of ownership of the NHS Pharmacy Contract previously held by Universal Pharmacy Limited (in administration) ("Universal"). This formally completes the acquisition of the assets from Universal as announced by the Company on 1 October 2025 - Link.

The Company is also pleased to provide an operational update for the period since its admission to trading on AIM on 26 August 2025.

NHS Contract Approval

On 4 November 2025, Norfolk and Waveney ICB approved the change of ownership application, marking the official transfer of Universal's NHS Distance Selling Pharmacy ("DSP") contract to MedPal Limited. This represents MedPal AI's first NHS contract and enables MedPal Limited to provide regulated NHS pharmaceutical services nationwide. The General Pharmaceutical Council ("GPhC") ceased issuing new DSP licences in June 2025, making this acquisition particularly significant.

Operational Update

MedPal AI app

The Company continues to develop its AI-driven wellness app, which aggregates data from over 100 wearables and health apps to provide personalised lifestyle guidance. The launch of MedPal.clinic completes the Company's dual-engine business model, creating a highly complementary flywheel that drives demand generation through the wellness app whilst fulfilling clinical needs through MedPal.clinic's regulated pharmacy services. This integrated approach combines AI-driven wellness insights with seamless access to prescription medications, positioning the Company uniquely in the digital healthcare market.

MedPal.clinic

Since the Company's announcement of the Acquisition on 1 October 2025, Medpal Limited dispensed 14,757 prescriptions, each written at least at the current NHS prescription charge of £9.90 per item. This strong initial performance demonstrates significant early demand for the Company's automated pharmacy services and validates its investment in advanced robotic dispensing technology.

The Company has also already received orders for weight loss drugs through its newly launched weight loss service at MedPal.clinic, which was announced on 7 November 2025. This early uptake is beyond the Board's expectations and reflects growing consumer demand for accessible telehealth services combined with rapid medication fulfilment.

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"We are delighted to announce the formal approval of our NHS contract from Norfolk and Waveney ICB. This milestone marks MedPal Limited's official entry into NHS pharmaceutical services and represents a significant validation of our operational capabilities.

"The strong trading performance since opening our distribution centre has exceeded our initial expectations, with nearly 15,000 prescription items dispensed in the 10 days of operation. This early momentum, combined with encouraging uptake of our private weight loss service, demonstrates the market appetite for our AI-enhanced, automated pharmacy model.

"We remain focused on scaling our operations efficiently whilst maintaining the highest standards of patient safety and service quality. The combination of our NHS contract, state-of-the-art automated dispensing capabilities, and growing private telehealth services positions us well for sustainable growth in the rapidly evolving digital healthcare market.

"The traditional pharmacy model is failing many users on cost, convenience, and accessibility. MedPal AI has built an integrated, AI-powered healthcare ecosystem that operates 24/7, making healthcare easily accessible and more affordable for everyone."

Listen to CEO Jason Drummond discuss the formal approval via the following link: https://www.voxmarkets.co.uk/articles/q-a-with-medpal-ai-ceo-jason-drummond-d9d2880

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company take responsibility for the contents of this announcement.

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END